Search

REGENXBIO Inc

Cerrado

SectorSanidad

10.75 1.22

Resumen

Variación precio

24h

Actual

Mínimo

10.29

Máximo

10.85

Métricas clave

By Trading Economics

Ingresos

113M

23M

Ventas

102M

108M

BPA

0.43

Margen de beneficios

21.023

Empleados

371

EBITDA

112M

34M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+132.46% upside

Dividendos

By Acuity

Próximas Ganancias

5 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

68M

688M

Apertura anterior

9.53

Cierre anterior

10.75

Noticias sobre sentimiento de mercado

By Acuity

86%

14%

328 / 340 Clasificación en Healthcare

REGENXBIO Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ago 2026, 19:36 UTC

Regenxbio Inc shares are higher during Friday's session, advancing despite a reported decline in retail sales for July.

13 ago 2026, 21:31 UTC

Regenxbio Inc shares are lower in after-market hours, pulling back from an earlier session high. No specific news was identified to explain the decline.

12 ago 2026, 19:41 UTC

Regenxbio Inc shares are higher today amid positive market sentiment following a modest increase in the core Consumer Price Index.

11 ago 2026, 19:11 UTC

Biotechnology stocks are advancing today, contributing to Regenxbio Inc's higher price movement. The stock pulled back earlier but remains in positive territory overall.

10 ago 2026, 19:46 UTC

News

Regenxbio Inc shares are lower today after H.C. Wainwright cut its price target to $23.00, despite a strong Q2 earnings report.

7 ago 2026, 20:06 UTC

News

Barclays downgraded Regenxbio Inc to Equal-Weight from Overweight, maintaining a $12 price target. Shares are trading lower amid concerns about growth prospects.

6 ago 2026, 23:31 UTC

News

Regenxbio Inc shares are higher in after-market hours following key milestones in its Q2 2026 earnings call, including FDA alignment for RGX-202's development.

5 ago 2026, 19:26 UTC

Regenxbio Inc shares are higher during Wednesday's session, despite intraday volatility. Broader market sentiment is influenced by a recent decline in crude oil prices.

4 ago 2026, 19:56 UTC

Regenxbio Inc shares are higher, reflecting market strength amid a decline in crude oil prices that eased inflation concerns. No specific company news was identified.

31 jul 2026, 19:36 UTC

Regenxbio Inc shares are lower, influenced by declines in the Biotechnology sector. The stock showed volatility, briefly rising earlier in the session.

30 jul 2026, 19:29 UTC

Regenxbio Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday. The stock remains below its 20-day moving average.

29 jul 2026, 19:56 UTC

Macro Event

Regenxbio Inc is trading higher as the Federal Reserve maintains interest rates, reflecting heightened market sensitivity amid ongoing economic growth and geopolitical tensions.

28 jul 2026, 18:16 UTC

Regenxbio Inc shares are lower, continuing a three-day decline amid broader market pressures, including losses in Asian markets like the Nikkei 225 Index.

27 jul 2026, 19:36 UTC

Regenxbio Inc is trading higher during Monday's session, recovering from earlier declines. Broader market sentiment is influenced by a significant drop in oil prices.

24 jul 2026, 20:07 UTC

Regenxbio Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average, indicating market weakness.

22 jul 2026, 18:26 UTC

Regenxbio Inc shares are lower amid geopolitical tensions and rising crude oil prices. Earlier in the session, shares briefly recovered but have since declined.

21 jul 2026, 19:31 UTC

Regenxbio Inc is higher during Tuesday's session, tracking the broader market's gains amid positive sentiment from recent earnings reports. No specific company news was identified.

20 jul 2026, 19:31 UTC

Event
News
Social Media

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.

Comparación entre iguales

Cambio de precio

REGENXBIO Inc previsión

Precio Objetivo

By TipRanks

132.46% repunte

Estimación a 12 Meses

Media 24.78 USD  132.46%

Máximo 45 USD

Mínimo 12 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para REGENXBIO Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

328 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
help-icon Live chat